Trevena Reported Topline Safety And Tolerability Data For The Two Phase 1 Proof-of-concept Studies Of TRV045
Portfolio Pulse from Benzinga Newsdesk
Trevena has reported positive topline safety and tolerability data for the two Phase 1 proof-of-concept studies of TRV045. The results were consistent with prior first-in-human study, with no drug-related adverse events, serious adverse events, lymphopenia, bradycardia, or change in blood pressure reported.
October 16, 2023 | 11:22 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive safety and tolerability data for Trevena's TRV045 could boost investor confidence in the company's drug development capabilities.
Positive safety and tolerability data from Phase 1 studies are critical for drug development. This news indicates that Trevena's TRV045 has passed an important milestone, which could increase investor confidence in the company's drug pipeline and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100